Valeant Pharmaceuticals International, Inc.
Thesis
Ackman discusses the challenges of GAAP accounting for companies like Valeant, suggesting that while it has been acquisitive, the focus should be on understanding the economic earnings rather than just reported earnings. This indicates a belief in the potential value of the company despite its accounting complexities.
Did it work?
inconclusive
confidence: low
The pitch expresses a general belief in Valeant's underlying value based on economic rather than GAAP earnings, but no price performance, time horizon, or specific catalysts are provided to test whether that value was realized. Without knowing the entry point, elapsed time, or subsequent price action, there is no way to confirm or refute the thesis. The verdict must therefore remain open.